AstraZeneca Signs Licensing Deal with China’s BioKangtai for 100 Million Doses of Oxford COVID-19 Vaccine by Year End
By HospiMedica International staff writers Posted on 11 Aug 2020 |
Illustration
AstraZeneca (Cambridgeshire, England) has signed a licensing deal with Chinese firm BioKangtai (Guangdong, Chin) to supply its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK), to China.
AstraZeneca announced the deal in a Chinese social media post and also stated that both the companies would explore the possibility of producing the vaccine for other markets as well, according to a FiercePharma report.
BioKangtai, a Chinese vaccine company, already produces a recombinant hepatitis B vaccine (Saccharomyces cerevisiae), an influenza type b conjugate vaccine and vaccines for measles and rubella. The company’s attenuated vaccines include a cell-free white-breaking Haemophilus influenzae type b combined vaccine, and 23-valent pneumococcal polysaccharide vaccine, among others.
As per the deal, AstraZeneca has granted exclusive clinical development, production and commercialization rights to the vaccine in China to BioKangtai, which will maintain sufficient capacity to produce a minimum of 100 million doses of the COVID-19 vaccine by 2020 end and increase its production to 200 million doses per year by the end of 2021. Overall, AstraZeneca aims to produce two billion doses of the vaccine globally by the end of 2021.
Related Links:
AstraZeneca
BioKangtai
University of Oxford
AstraZeneca announced the deal in a Chinese social media post and also stated that both the companies would explore the possibility of producing the vaccine for other markets as well, according to a FiercePharma report.
BioKangtai, a Chinese vaccine company, already produces a recombinant hepatitis B vaccine (Saccharomyces cerevisiae), an influenza type b conjugate vaccine and vaccines for measles and rubella. The company’s attenuated vaccines include a cell-free white-breaking Haemophilus influenzae type b combined vaccine, and 23-valent pneumococcal polysaccharide vaccine, among others.
As per the deal, AstraZeneca has granted exclusive clinical development, production and commercialization rights to the vaccine in China to BioKangtai, which will maintain sufficient capacity to produce a minimum of 100 million doses of the COVID-19 vaccine by 2020 end and increase its production to 200 million doses per year by the end of 2021. Overall, AstraZeneca aims to produce two billion doses of the vaccine globally by the end of 2021.
Related Links:
AstraZeneca
BioKangtai
University of Oxford
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans